DUX4 and facioscapulohumeral muscular dystrophy: Both studies demonstrated the efficacy of morpholino-mediated DUX4 transcription inhibition in a dose-dependent manner in primary FSHD myoblasts [47], immortalized FSHD clones [46,48], and in a xenograft mouse model [47,49].